Capricor Therapeutics (NASDAQ:CAPR) Cut to “Neutral” at Roth Capital

Roth Capital lowered shares of Capricor Therapeutics (NASDAQ:CAPR) from a buy rating to a neutral rating in a research note published on Monday morning, MarketBeat.com reports. Roth Capital currently has $7.00 target price on the biotechnology company’s stock.

A number of other equities analysts have also recently commented on CAPR. Oppenheimer reaffirmed an “outperform” rating on shares of Capricor Therapeutics in a research note on Monday. LADENBURG THALM/SH SH raised Capricor Therapeutics to a “strong-buy” rating in a research note on Thursday, June 25th. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. Finally, B. Riley Financial lowered shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $10.00 price target for the company. in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Capricor Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $40.60.

Capricor Therapeutics Trading Up 1.5%

CAPR opened at $6.67 on Monday. Capricor Therapeutics has a 12 month low of $4.30 and a 12 month high of $40.37. The business’s 50-day moving average price is $24.01 and its 200-day moving average price is $27.07. The company has a market cap of $386.26 million, a P/E ratio of -2.88 and a beta of 0.42.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Equities research analysts forecast that Capricor Therapeutics will post -0.49 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Anthony Bergmann sold 24,100 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the transaction, the chief financial officer owned 11,223 shares in the company, valued at $340,954.74. The trade was a 68.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 50,000 shares of company stock valued at $1,551,658 over the last quarter. 9.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Suvretta Capital Management LLC bought a new stake in shares of Capricor Therapeutics in the 4th quarter worth approximately $51,533,000. Tang Capital Management LLC bought a new position in shares of Capricor Therapeutics during the fourth quarter valued at approximately $49,062,000. RA Capital Management L.P. bought a new position in shares of Capricor Therapeutics during the fourth quarter valued at approximately $43,516,000. Darwin Global Management Ltd. bought a new position in shares of Capricor Therapeutics during the fourth quarter valued at approximately $23,168,000. Finally, SB Capital Management Inc purchased a new stake in Capricor Therapeutics in the fourth quarter worth $11,544,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Key Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Supportive clinical publication: The Lancet published HOPE-3 Phase 3 data showing that deramiocel slowed upper-limb functional decline by 54% versus placebo and demonstrated potential cardiac benefits. Capricor said the publication independently validated the trial’s design, methodology and findings. The Lancet Publishes HOPE-3 Data
• Neutral Sentiment: Trading halt and valuation data: CAPR trading was temporarily halted for pending news ahead of the FDA panel decision. A reported analyst consensus price target of about $53.67 is now largely disconnected from the stock’s recent trading level, while B. Riley maintained a neutral rating. Capricor Receives Average Analyst Price Target
• Negative Sentiment: FDA panel rejects demonstrated benefit: Independent FDA advisers voted against deramiocel’s benefits for Duchenne-related cardiomyopathy. FDA briefing materials questioned Capricor’s claim that the treatment produced statistically significant benefits on its prespecified cardiac endpoint, creating substantial uncertainty around approval. FDA Panel Votes Against Capricor Therapy
• Negative Sentiment: Analyst downgrades: B. Riley and Roth Capital downgraded Capricor following the FDA vote, adding to Alliance Global Partners’ prior cut from “buy” to “neutral” with a $7 price target. The downgrades signal reduced confidence in the drug’s near-term commercial potential. Capricor Shares Fall After Analyst Downgrades
• Negative Sentiment: Investor investigations: Several law firms announced investigations into potential securities-law violations related to Capricor’s disclosures and the FDA review. These announcements do not establish wrongdoing but may add legal costs, reputational risk and selling pressure.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.